



ASX Release

5 December 2024

Cleansing notice pursuant to share purchase plan

Melbourne, Australia; Acrux Limited (ASX:ACR)

Acrux Limited (ASX:ACR) (**Company** or **Acrux**) refers to its announcement to ASX today that it will make offers to issue fully paid ordinary shares (**Shares**) under a share purchase plan that is scheduled to open on 6 December 2024.

The Company gives this notice in accordance with *ASIC Corporations (Share and Interest Purchase Plans) Instrument 2019/547 (Instrument)*.

In accordance with the Instrument, the Company gives notice that:

- (1) it will make offers to issue Shares under the share purchase plan without disclosure to investors under Part 6D.2 of the *Corporations Act 2001* (Cth) (**Act**);
- (2) this notice is being given in accordance with the Instrument;
- (3) as at the date of this notice, it has complied with:
 - (a) the provisions of Chapter 2M of the Act as they apply to the Company; and
 - (b) section 674 of the Act; and
- (4) as at the date of this notice, there is no information that is “excluded information” (as defined in sections 708A(7) and (8) of the Act) which is required to be disclosed by the Company (as if this notice were a notice under section 708A(5)(e) of the Act).

This announcement has been authorised for release to the ASX by the Board of Directors.

For more information, please contact:

Michael Kotsanis

CEO & Managing Director

E: michael.kotsanis@acrux.com.au

Joanna Johnson

CFO & Company Secretary

E: joanna.johnson@acrux.com.au

P: + 61 3 8379 0100

About Acrux

Acrux is a specialty pharma company with a successful track record of developing and commercialising a pipeline of topically applied pharmaceutical products. Drawing on 25 years of experience, Acrux has successfully marketed through licensees a number of products worldwide with emphasis on the United States. Acrux is formulating and developing a range of topical generic products by leveraging its highly skilled workforce, on-site laboratories, GMP manufacturing suite, technical, clinical and commercial experience to bring affordable products to market. Acrux encourages collaboration and is well positioned to discuss commercial partnering and product development opportunities. For further information on Acrux, visit: www.acrux.com.au